TYLER, Texas / May 28, 2025 / Business Wire / NanoVibronix, Inc. (the “Company”) (NASDAQ: NAOV) confirmed that a series of posts made earlier today with respect to a $26 million registered direct offering of common stock of the Company priced at $0.45 under Nasdaq rules was falsely issued by Flash Alert and FintelAlerts. The Company has not priced and is not consummating any registered direct offering. The Company is actively investigating this misinformation and will take necessary actions to protect its stockholders and its reputation.
| Last Trade: | US$5.48 |
| Daily Change: | 0.06 1.11 |
| Daily Volume: | 5,212 |
| Market Cap: | US$4.370M |
July 18, 2025 June 11, 2025 June 04, 2025 | |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORE
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
